Breast‐Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application

Selective, sensitive, and specific breast cancer diagnosis: Neuropeptide Y (NPY) and the Y1R-selective [Phe7, Pro34]NPY peptide were labeled with Re/99mTc and pre-clinically characterized using competition receptor binding and signal transduction assays, and also microscopic, metabolic-stability, rabbit body-uptake, and protein-binding studies. Selective uptake of the 99mTc(core)3+-(NαHis-ac)-labeled [Phe7, Pro34]NPY analogue in human breast-cancer patients was obtained by whole body scintimammography.